Extraskeletal Ewing sarcoma: Diagnosis, management and prognosis (Review)

dc.contributor.authorAbboud, Abdallah
dc.contributor.authorMasrouha, Karim Z.
dc.contributor.authorSaliba, Maelle
dc.contributor.authorHaidar, Rachid K.
dc.contributor.authorSaab, Raya H.
dc.contributor.authorKhoury, Nabil El
dc.contributor.authorTawil, Ayman N.
dc.contributor.authorSaghieh, Saïd S.
dc.contributor.departmentSurgery
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.departmentDiagnostic Radiology
dc.contributor.departmentDivision Of Orthopedic Surgery
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:13:24Z
dc.date.available2025-01-24T12:13:24Z
dc.date.issued2021
dc.description.abstractExtraskeletal Ewing sarcoma (EES) is a relatively uncommon primary tumor of the soft tissues, which accounts for 20‑30% of all reported cases of ES. Being uncommon, all members of the ES family tumors are treated following the same general protocol of sarcoma tumors. The present review summarizes the diagnosis, management and prognosis of EES, focusing on the differences between the subtypes of ESS. The clinical features and imaging of EES are also discussed. Magnetic resonance imaging is the modality of choice for diagnostic imaging and local staging, while core‑needle biopsy with pathological testing is used to obtain a definitive diagnosis. Although several oncology groups endorse that ES family of tumors should be treated with similar algorithm and protocols, some studies have demonstrated that surgery and radiotherapy may be used as a form of local control. However, further studies are required to conclude the optimum treatment option for EES. © 2021 Spandidos Publications. All rights reserved.
dc.identifier.doihttps://doi.org/10.3892/ol.2021.12615
dc.identifier.eid2-s2.0-85102489499
dc.identifier.urihttp://hdl.handle.net/10938/33031
dc.language.isoen
dc.publisherSpandidos Publications
dc.relation.ispartofOncology Letters
dc.sourceScopus
dc.subjectDiagnosis
dc.subjectEwing sarcoma
dc.subjectPrognosis
dc.subjectTherapy
dc.subjectCd99 antigen
dc.subjectCyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus vincristine
dc.subjectFilgrastim
dc.subjectFluorodeoxyglucose f 18
dc.subjectGadolinium
dc.subjectIfosfamide
dc.subjectProtein s 100
dc.subjectSynaptophysin
dc.subjectBone metastasis
dc.subjectCancer chemotherapy
dc.subjectCancer diagnosis
dc.subjectCancer prognosis
dc.subjectCancer radiotherapy
dc.subjectCancer staging
dc.subjectCancer surgery
dc.subjectChemoradiotherapy
dc.subjectComputer assisted tomography
dc.subjectDiagnostic imaging
dc.subjectEchography
dc.subjectExtraskeletal ewing sarcoma
dc.subjectFluorescence in situ hybridization
dc.subjectGenetic analysis
dc.subjectHistology
dc.subjectHuman
dc.subjectImmunohistochemistry
dc.subjectIncidence
dc.subjectMetastasis
dc.subjectMolecular genetics
dc.subjectNeedle biopsy
dc.subjectNeoadjuvant chemotherapy
dc.subjectNuclear magnetic resonance imaging
dc.subjectOverall survival
dc.subjectPositron emission tomography
dc.subjectPositron emission tomography-computed tomography
dc.subjectPrevalence
dc.subjectRadiation dose
dc.subjectReverse transcription polymerase chain reaction
dc.subjectReview
dc.subjectRisk factor
dc.subjectSurvival rate
dc.subjectTumor volume
dc.titleExtraskeletal Ewing sarcoma: Diagnosis, management and prognosis (Review)
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-6019.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format